ストックスクリーナーアプリを入手
13.33
0.30%
0.04
アフターアワーズ：
13.33
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Weekly Upgrades and Downgrades - InvestorPlace
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily
Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily
Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily
Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News
North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily
AHH stock rated a Buy by Stifel - Knox Daily
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily
Brookline Bancorp, Inc. [BRKL] Records 50-Day SMA of $10.01 - Knox Daily
Crescent Energy Co. [CRGY] Records 200-Day SMA of $11.56 - Knox Daily
Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily
TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Ipsen provides update on CONTACT-02 Phase III trial in - GlobeNewswire
Biotech Soars, And Then Dives, On $5 Billion Opportunity - Investor's Business Daily
0.74%
大文字化:
|
ボリューム (24 時間):